ProQR Therapeutics (NASDAQ:PRQR) Releases Earnings Results, Misses Estimates By $0.02 EPS

ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02), Zacks reports. The business had revenue of $3.38 million during the quarter, compared to analyst estimates of $7.05 million. ProQR Therapeutics had a negative net margin of 273.20% and a negative return on equity of 55.54%.

ProQR Therapeutics Trading Up 0.5%

NASDAQ:PRQR traded up $0.01 during trading hours on Friday, hitting $2.22. 526,627 shares of the company traded hands, compared to its average volume of 600,782. ProQR Therapeutics has a twelve month low of $1.07 and a twelve month high of $4.21. The firm has a 50-day moving average of $2.40 and a 200 day moving average of $2.11. The stock has a market capitalization of $233.57 million, a price-to-earnings ratio of -4.72 and a beta of 0.16.

Institutional Investors Weigh In On ProQR Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. increased its stake in ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 4,500 shares during the period. Jane Street Group LLC lifted its position in shares of ProQR Therapeutics by 699.3% in the 1st quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 79,720 shares during the period. Bank of America Corp DE grew its holdings in shares of ProQR Therapeutics by 25.7% during the 2nd quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 24,347 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of ProQR Therapeutics by 28.4% during the second quarter. BNP Paribas Financial Markets now owns 121,494 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 26,893 shares during the period. 32.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PRQR. Evercore ISI restated an “outperform” rating on shares of ProQR Therapeutics in a report on Friday, July 11th. Zacks Research downgraded ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 15th. Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Wednesday, October 8th. Finally, Chardan Capital reiterated a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a report on Tuesday. Seven analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.14.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).